AI-Powered Conversational Data Intelligence for Healthcare Marketing 

Talking Medicines, a trailblazing company based in Glasgow, Scotland, is revolutionizing healthcare marketing with its cutting-edge AI-driven solutions. Leveraging advanced data science and natural language processing, the company is transforming how pharmaceutical companies and healthcare agencies understand and engage with Healthcare Professionals and patients. 

Founded in 2013, Talking Medicines has introduced innovative tools such as their flagship product, Drug-GPT, which extracts actionable intelligence from unstructured data. By analyzing patient and Healthcare Professional experiences by drug, Talking Medicines delivers unparalleled insights that empower pharmaceutical companies to refine their strategies and achieve patient-centric marketing goals. 

New Opportunities in the US Market 

In an exciting development, Talking Medicines has been selected as one of five pioneering Scottish companies to participate in Scottish Enterprise’s US MarketBooster Programme. This initiative is designed to accelerate the growth of Scottish science and tech companies in the competitive US market. For Talking Medicines, the program is a significant milestone in its journey to scale operations and expand its footprint in the world’s largest market for technology products and services. 

The US MarketBooster Programme aligns with Scottish Enterprise’s broader mission to double the number of scaling companies in Scotland over the next decade. By focusing on economic transformation, this program offers targeted, wraparound support to help companies like Talking Medicines gain the expertise, networks, and skills needed to thrive in the US market. 

Accelerating US Scalability 

Talking Medicines sees the US Market Booster Programme as a catalyst for growth. According to co-founder Jo Halliday: 

“We’ve been supported by Scottish Enterprise over the years in many useful ways, and their help means you can go further, faster, and bring the benefit into your business and bottom line sooner. 

We’re very excited to be involved in this program alongside other scaling companies looking to expand and go big in the United States. Talking Medicines already has a successful presence in the US, and this programme will further accelerate our scalability in 2025 through the extension of our current market and growth of AI.” 

Pioneering Scottish Innovation in Healthcare Data 

Talking Medicines participation in the US Market Booster Programme highlights Scotland’s vibrant ecosystem of innovation. Alongside companies specializing in AI, cloud computing, and cybersecurity, Talking Medicines represents the forefront of healthcare data analytics and patient-centric solutions. 

As part of this cohort, Talking Medicines aims to achieve US revenue growth 6-12 months faster than traditional timelines. By leveraging the support provided by Scottish Enterprise and Silicon Valley networks, the company is well-positioned to lead the way in healthcare marketing transformation. 

Conclusion 

Talking Medicines journey to Silicon Valley marks a pivotal step in its mission to redefine healthcare marketing through AI and data intelligence. With the support of the US Market Booster Programme, Talking Medicines is ready to make a lasting impact in the US healthcare market, driving innovation, scalability, and patient-centered insights. 

For more information on Talking Medicines and its groundbreaking solutions, follow their updates on LinkedIn as they continue their exciting journey in Silicon Valley.